Kepler Capital Keeps Their Buy Rating on GFT Technologies (0O2W)
Kepler Capital analyst Sven Sauer maintained a Buy rating on GFT Technologies (0O2W – Research Report) on May 8 and set a price target of €29.00. The company's shares closed yesterday at €24.35.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
According to TipRanks, Sauer is a 4-star analyst with an average return of 6.0% and a 44.89% success rate.
Currently, the analyst consensus on GFT Technologies is a Strong Buy with an average price target of €32.00, a 31.42% upside from current levels. In a report released on May 8, Warburg Research also maintained a Buy rating on the stock with a €36.00 price target.
Based on GFT Technologies' latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of €225.38 million and a net profit of €12.62 million. In comparison, last year the company earned a revenue of €207.13 million and had a net profit of €13.52 million
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
37 minutes ago
- Business Insider
Coca-Cola Stock (KO) Could Benefit by Leaving Bottling Behind
Coca-Cola (KO) has slowly been moving away from bottling its own beverages, leaving that work to other companies that it sells syrup to. The company has been shifting toward this model for years now and has continued to do so with recent plant closures and layoffs. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter The latest Coca-Cola layoffs include 135 jobs that were cut in Napa County, Calif. The soda maker has closed this 30-year-old plant as part of its strategic change away from bottling its own products. When Coca-Cola's plan is complete, 80% of its bottling will be outsourced to other companies. It makes sense that Coca-Cola would seek to reduce its bottling and outsource the process. Doing so makes the company more asset-light and allows it to focus on its syrup margins of 68%. For comparison, the margins for bottling are only 12%. Offloading those less profitable operations could help boost KO stock. KO Stock Analyst Coverage Analysts largely agree with this mentality, with continued praise for KO stock. That includes updates from two analysts earlier this week: Five-star Morgan Stanley analyst Dara Mohsenian reiterated a Buy rating and an $81 price target, suggesting a 12.17% upside. RBC Capital analyst Nik Modi maintained a Buy rating and a $76 price target, implying a 5.25% upside. KO stock was up 0.64% as of Tuesday morning. That builds on its 16.88% increase year-to-date and its 12.93% rally over the past 12 months. Is KO Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Coca-Cola is Strong Buy, based on 15 Buy ratings and a single Hold rating over the past three months. With that comes an average KO stock price target of $79.50, representing a potential 10.08% upside for the shares.
Business Insider
an hour ago
- Business Insider
Mizuho Securities Keeps Their Buy Rating on Insmed (INSM)
In a report released yesterday, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Insmed (INSM – Research Report), with a price target of $110.00. The company's shares closed yesterday at $90.93. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Suvannavejh is an analyst with an average return of -7.4% and a 41.75% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Verastem, and Harmony Biosciences Holdings. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Insmed with a $98.36 average price target, implying an 8.17% upside from current levels. In a report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $94.00 price target. INSM market cap is currently $13.41B and has a P/E ratio of -11.88. Based on the recent corporate insider activity of 120 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of INSM in relation to earlier this year. Earlier this month, Orlov Nicole Schaeffer, the Chief People Strategy Officer of INSM sold 1,642.00 shares for a total of $117,403.00.
Business Insider
an hour ago
- Business Insider
Danske Bank (0NVC) Gets a Buy from Kepler Capital
Kepler Capital analyst Markus Sandgren maintained a Buy rating on Danske Bank (0NVC – Research Report) on June 9 and set a price target of DKK245.00. The company's shares closed last Friday at DKK259.30. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Sandgren covers the Financial sector, focusing on stocks such as Intrum Justitia AB, Svenska Handelsbanken AB, and Collector AB. According to TipRanks, Sandgren has an average return of 13.2% and an 88.89% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Danske Bank with a DKK272.00 average price target, representing a 4.90% upside. In a report released on June 2, Barclays also upgraded the stock to a Buy with a DKK289.00 price target.
